[EN] SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS [FR] DÉRIVÉS DE CARBOXAMIDE ET D'URÉE À BASE DE PYRAZOLYLE SUBSTITUÉ PORTANT UN FRAGMENT PHÉNYLE REMPLACÉ PAR UN GROUPE CONTENANT O COMME LIGANDS DES RÉCEPTEURS VANILLOÏDES
[EN] SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS [FR] DÉRIVÉS DE CARBOXAMIDE ET D'URÉE À BASE DE PYRAZOLYLE SUBSTITUÉ PORTANT UN FRAGMENT PHÉNYLE REMPLACÉ PAR UN GROUPE CONTENANT O COMME LIGANDS DES RÉCEPTEURS VANILLOÏDES
Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands
申请人:FRANK Robert
公开号:US20120258946A1
公开(公告)日:2012-10-11
Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
Substituted phenylureas and phenylamides as vanilloid receptor ligands
申请人:Frank Robert
公开号:US08946204B2
公开(公告)日:2015-02-03
Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
取代苯脲和苯酰胺,其制备方法,含有这些化合物的药物组合物以及使用这些化合物制备药物组合物。
8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER
申请人:Campbell David
公开号:US20140163026A1
公开(公告)日:2014-06-12
Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.
8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER
申请人:Afraxis Holdings, Inc.
公开号:EP2694504A2
公开(公告)日:2014-02-12
SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS